Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Eli Lilly has taken a significant step towards making weight loss medications more accessible by reducing the price of their drug ZepBound. In an effort to combat cost and coverage hurdles, the ...

Tue, December 2, 2025 at 9:20 PM UTC “Her Publicist’s Face Says It All”: People Are Appalled At This Viral Clip Of Cynthia Erivo Repeatedly Being Called “Tough” In An Uncomfortable Interview ...

Frigid Saturday night into Sunday morning. Milder weather in the new week with the next weather maker. It’s not just cold outside in central Wisconsin; it’s dangerously cold. The experts at the Wausau ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...

Dec 1 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S.

Popular drugs like Zepbound and Wegovy that promise a slimmer profile can trigger much more than weight loss. These medications can spur a slew of potential side effects, like nausea, vomiting, ...